Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.313 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
PURPOSE: EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy. PATIENTS AND METHODS: At diagnosis, patients age ≤ 40 years with resectable high-grade osteosarcoma were registered. Eligibility after surgery for good response random assignment included ≥ two cycles of preoperative MAP (methotrexate, doxorubicin, and cisplatin), macroscopically complete surgery of primary tumor, < 10% viable tumor, and no disease progression. These patients were randomly assigned to four additional cycles MAP with or without IFN-α-2b (0.5 to 1.0 μg/kg per week subcutaneously, after chemotherapy until 2 years postregistration). Outcome measures were event-free survival (EFS; primary) and overall survival and toxicity (secondary). RESULTS: Good response was reported in 1,041 of 2,260 registered patients; 716 consented to random assignment (MAP, n = 359; MAP plus IFN-α-2b, n = 357), with baseline characteristics balanced by arm. A total of 271 of 357 started IFN-α-2b; 105 stopped early, and 38 continued to receive treatment at data freeze. Refusal and toxicity were the main reasons for never starting IFN-α-2b and for stopping prematurely, respectively. Median IFN-α-2b duration, if started, was 67 weeks. A total of 133 of 268 patients who started IFN-α-2b and provided toxicity information reported grade ≥ 3 toxicity during IFN-α-2b treatment. With median follow-up of 44 months, 3-year EFS for all 716 randomly assigned patients was 76% (95% CI, 72% to 79%); 174 EFS events were reported (MAP, n = 93; MAP plus IFN-α-2b, n = 81). Hazard ratio was 0.83 (95% CI, 0.61 to 1.12; P = .214) from an adjusted Cox model. CONCLUSION: At the preplanned analysis time, MAP plus IFN-α-2b was not statistically different from MAP alone. A considerable proportion of patients never started IFN-α-2b or stopped prematurely. Long-term follow-up for events and survival continues.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- Journal of Clinical Oncology
- Topic
- Sarcoma Diagnosis and Treatment
- Field
- Medicine
- Canadian institutions
- —
- Funders
- CilagChildren's Hospital of PittsburghUniversity College LondonNational Cancer InstituteUniversity of NottinghamHospital for Sick ChildrenDeutsche KrebshilfeUniversitair Medisch Centrum GroningenConnecticut Children's Medical CenterMedical Research CouncilChildren’s Oncology GroupLeids Universitair Medisch CentrumDalhousie UniversityCliniques Universitaires Saint-LucChildren's Hospitals and Clinics of MinnesotaBundesministerium für Bildung und ForschungRadboud UniversiteitChildren's Hospital ColoradoCleveland ClinicUniversiteit LeidenUniversität WienDeutsche ForschungsgemeinschaftEuropean Science FoundationUniversity of LeedsCancer Research UKCedars-Sinai Medical CenterUniversitätsspital BaselMemorial Sloan-Kettering Cancer CenterOchsner HealthSaint Luke's Health SystemEuropean CommissionNationwide Children's HospitalHelsingin YliopistoChildren's Healthcare of AtlantaVlaamse regeringNational Institute for Health and Care ResearchBC Children's HospitalArcadia FundMedizinische Universität WienCarilion ClinicNorges ForskningsrådPennsylvania State UniversitySundhed og Sygdom, Det Frie ForskningsrådCleveland Clinic FoundationCincinnati Children's Hospital Medical CenterChildren's National HospitalUniversity of PennsylvaniaChildren's Hospital of Philadelphia
- Keywords
- MedicineChemotherapySurgeryMethotrexateToxicityCisplatinOsteosarcomaDoxorubicinInternal medicineGastroenterologyUrologyPathology
- Has abstract in OpenAlex
- yes